Comparison of the Effect of Unilateral Intravitreal Bevacizumab and Ranibizumab Injection on Diabetic Macular Edema of the Fellow Eye

Basit Öğe Kaydı
dc.contributor.authorBakbak, Berker
dc.contributor.authorOzturk, Banu Turgut
dc.contributor.authorGonul, Saban
dc.contributor.authorYilmaz, Mevlut
dc.contributor.authorGedik, Sansal
dc.date.accessioned2020-03-26T18:41:20Z
dc.date.available2020-03-26T18:41:20Z
dc.date.issued2013
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractPurpose: To find out whether intravitreally administered bevacizumab and ranibizumab affect the contralateral, untreated, eyes of patients with bilateral diabetic macular edema (DME). Methods: A retrospective review of patients with bilateral DME, who were treated with intravitreal bevacizumab or ranibizumab, was performed. All enrolled patients received intravitreal 1.25mg bevacizumab or 0.5mg ranibizumab in the eye with more severe macular edema. As outcome measures, best-corrected visual acuity (BCVA) was assessed with the Early Treatment Diabetic Retinopathy Study chart and central foveal thickness (CFT) measurement was obtained using optical coherence tomography-3 before and at 2 and 4 weeks after injections. Results: The study included 55 eyes of 55 patients who received bevacizumab (group 1) and 32 eyes of 32 patients who received ranibizumab (group 2). The mean age of the 55 patients [35 female (63.6%), 20 male (36.4%)] in group 1 was 54.3112.67 years, and the mean age of the 32 patients [20 female (62.5%), 12 male (37.5%)] in group 2 was 56.01 +/- 13.29 years. The median BCVA in the uninjected eye showed no statistically significant change at any visit after either bevacizumab or ranibizumab injection (P=0.302, P=0.582, respectively). In group 1, the median CFT in the uninjected eye was 417m at baseline; this was reduced to 401m at 2 weeks and 372m at 4 weeks. The change in CFT was found to be statistically significant (P=0.009). No statistically significant change was found in the median CFT of uninjected eyes of patients treated with ranibizumab (399, 403, and 407m before and at 2 and 4 weeks after treatment, respectively). Conclusions: Compared with ranibizumab, intravitreal administration of bevacizumab resulted in a greater decrease in macular thickness in the untreated eye, in patients with bilateral DME.en_US
dc.description.sponsorshipScientific Research Coordination Center of Selcuk UniversitySelcuk University [BAP-12701901]en_US
dc.description.sponsorshipThis study is supported by The Scientific Research Coordination Center of Selcuk University (BAP-12701901).en_US
dc.identifier.doi10.1089/jop.2013.0049en_US
dc.identifier.endpage732en_US
dc.identifier.issn1080-7683en_US
dc.identifier.issn1557-7732en_US
dc.identifier.issue8en_US
dc.identifier.pmid23848950en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage728en_US
dc.identifier.urihttps://dx.doi.org/10.1089/jop.2013.0049
dc.identifier.urihttps://hdl.handle.net/20.500.12395/29319
dc.identifier.volume29en_US
dc.identifier.wosWOS:000324915900006en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherMARY ANN LIEBERT, INCen_US
dc.relation.ispartofJOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICSen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.titleComparison of the Effect of Unilateral Intravitreal Bevacizumab and Ranibizumab Injection on Diabetic Macular Edema of the Fellow Eyeen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu